Neuronetics Showcases New NeuroStar® TMS Findings at Clinical TMS Society Annual Meeting
Data highlights the Company’s commitment to advancing TMS and improving patient outcomesMALVERN, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Neuronetics,...
Mental Health
NeuroStar® Expands “Tap Into Possibility” Campaign in Honor of Mental Health Awareness Month
Campaign features patients’ experiences to support others with depression A Media Snippet accompanying this announcement is available by clicking on the...
Neuronetics Announces Lisa Metzner-Rosas as SVP, Chief Marketing Officer
Strategic role strengthens NeuroStar® Advanced Therapy commercialization teamMALVERN, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a...
Axsome Therapeutics Joins Mental Health America and the State of New York to Raise Awareness of Mental Health During May is Mental Health Month
One World Trade Center to be lit up in green in observance of Mental Health MonthNEW YORK, May 01, 2023...
Neuronetics Announces Expanded TMS Access through United HealthCare
UHC Medicare Advantage plans in NGS states expand access via NPPsMALVERN, Pa., April 28, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc....
Neuronetics to Report First Quarter 2023 Financial and Operating Results and Host Conference Call
MALVERN, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on...
Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression
The application is for a novel psychedelic-based combination, of Clearmind's MEAI and SciSparc's Cannamide™ Tel Aviv, Israel / Vancouver, Canada,...
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression
The application refers to a novel psychedelic-based combination of Clearmind's MEAI and SciSparc's Cannamide™ TEL AVIV, Israel, April 21, 2023 (GLOBE NEWSWIRE)...
Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of Neurology (AAN) Annual Meeting
NEW YORK, April 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
Baycrest’s Goal Management Training Now Offered Through Telus Health’s AbilitiCBT Platform
First large-scale digital roll out of Baycrest’s Goal Management Training will support mental rehabilitation for people across Canada and the...
Orphalan announces US commercial launch of Cuvrior™ for the treatment of Wilson disease
Cuvrior™ now available in the US for the treatment of adult patients with stable Wilson disease who are de-coppered and...
77% of Americans have used addictive behaviors or unhealthy coping mechanisms to manage their mental health, according to Myriad Genetics nationwide survey
Medication failure leads 45% of respondents with depression and/or anxiety to turn to unhealthy coping mechanisms Respondents may view these behaviors...
RevMed Commits to Supporting Local and Global Charities
Healthcare supply chain software company plans to donate 5% of all proceeds to charitiesDALLAS, April 14, 2023 (GLOBE NEWSWIRE) --...
Neuronetics Announces Continued Momentum for Expanded Health Insurance Coverage for TMS Therapy
BlueCross BlueShield of Mississippi Latest to Allow Non-Physician Practitioners to Prescribe TMSMALVERN, Pa., April 13, 2023 (GLOBE NEWSWIRE) -- Neuronetics,...
Eminent Trauma Researcher Dr. Lipov and Author Jamie Mustard Release New Book to Introduce Revolutionary PTSD Treatment to the Masses
“The Invisible Machine” reveals the startling truth about trauma and the scientific breakthrough that could transform millions of lives The...
Accolade to Announce Fiscal Fourth Quarter 2023 Financial Results
SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced...
Oshi Health Raises $30M Series B Funding to Scale Access to Its Virtual Multidisciplinary Digestive Care
New investor Koch Disruptive Technologies joins existing investors to reinforce Oshi’s market lead and address surging demand from patients, employers,...
Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research
— Presentation entitled "BMB-101: A selective 5-HT2C agonist in clinical trials with therapeutic utility" — — First-in-human Phase 1 trial for lead program,...
The Hazelden Betty Ford Foundation and TELUS Health collaborate to expand substance use disorder treatment and mental health support
CENTER CITY, Minn. and VANCOUVER, British Columbia, April 05, 2023 (GLOBE NEWSWIRE) -- The Hazelden Betty Ford Foundation and TELUS...
Neuronetics Secures Up To $60 Million in New Debt Financing with SLR Capital Partners, Provides Greenbrook TMS with $6.0 Million Promissory Note
MALVERN, Pa., April 04, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a...